Abstract

Understanding how the brain recovers from unconsciousness can inform neurobiological theories of consciousness and guide clinical investigation. To address this question, we conducted a multicenter study of 60 healthy humans, half of whom received general anesthesia for three hours and half of whom served as awake controls. We administered a battery of neurocognitive tests and recorded electroencephalography to assess cortical dynamics. We hypothesized that recovery of consciousness and cognition is an extended process, with differential recovery of cognitive functions that would commence with return of responsiveness and end with return of executive function, mediated by prefrontal cortex. We found that, just prior to the recovery of consciousness, frontal-parietal dynamics returned to baseline. Consistent with our hypothesis, cognitive reconstitution after anesthesia evolved over time. Contrary to our hypothesis, executive function returned first. Early engagement of prefrontal cortex in recovery of consciousness and cognition is consistent with global neuronal workspace theory.

Data availability

All data generated or analyzed during this study are included in the manuscript and supporting files. Source data have been provided for Figures 2-5.

Article and author information

Author details

  1. George A Mashour

    Anesthesiology; Neuroscience, University of Michigan, Ann Arbor, United States
    For correspondence
    gmashour@umich.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5457-5932
  2. Ben JA Palanca

    Anesthesiology, Washington University, St. Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Mathias Basner

    Psychiatry, University of Pennsylvania, Philadelphia, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Duan Li

    Anesthesiology, University of Michigan, Ann Arbor, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Wei Wang

    Statistics, Washington University, St. Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Stephanie Blain-Moraes

    Occupational Therapy; Biomedical Engineering, McGill University, Montreal, Canada
    Competing interests
    The authors declare that no competing interests exist.
  7. Nan Lin

    Statistics, Washington University, St. Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Kaitlyn Maier

    Anesthesiology, University of Pennsylvania, Philadelphia, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Maxwell Muench

    Anesthesiology, Washington University, St. Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Vijay Tarnal

    Anesthesiology, University of Michigan, Ann Arbor, United States
    Competing interests
    The authors declare that no competing interests exist.
  11. Giancarlo Vanini

    Anesthesiology; Neuroscience, University of Michigan, Ann Arbor, United States
    Competing interests
    The authors declare that no competing interests exist.
  12. E Andrew Ochroch

    Anesthesiology, University of Pennsylvania, Philadelphia, United States
    Competing interests
    The authors declare that no competing interests exist.
  13. Rosemary Hogg

    Anesthesiology, University of Pennsylvania, Philadelphia, United States
    Competing interests
    The authors declare that no competing interests exist.
  14. Marlon Schwartz

    Anesthesiology, University of Pennsylvania, Philadelphia, United States
    Competing interests
    The authors declare that no competing interests exist.
  15. Hannah Maybrier

    Anesthesiology, Washington University, St. Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
  16. Randall Hardie

    Anesthesiology, University of Pennsylvania, Philadelphia, United States
    Competing interests
    The authors declare that no competing interests exist.
  17. Ellen Janke

    Anesthesiology, University of Michigan, Ann Arbor, United States
    Competing interests
    The authors declare that no competing interests exist.
  18. Goodarz Golmirzaie

    Anesthesiology, University of Michigan, Ann Arbor, United States
    Competing interests
    The authors declare that no competing interests exist.
  19. Paul Picton

    Anesthesiology, University of Michigan, Ann Arbor, United States
    Competing interests
    The authors declare that no competing interests exist.
  20. Andrew R McKinstry-Wu

    Anesthesiology, University of Pennsylvania, Philadelphia, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7078-4603
  21. Michael S Avidan

    Anesthesiology, Washington University, St. Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
  22. Max B Kelz

    Bioengineering, Anesthesiology and Critical Care, University of Pennsylvania, Philadelphia, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2803-6078

Funding

James S. McDonnell Foundation (Understanding Human Cognition)

  • George A Mashour

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: The study received ethics committee approval from the University of Michigan, Washington University, and the University of Pennsylvania; written informed consent was obtained after careful discussion with each participant.

Copyright

© 2021, Mashour et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 12,469
    views
  • 1,392
    downloads
  • 63
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. George A Mashour
  2. Ben JA Palanca
  3. Mathias Basner
  4. Duan Li
  5. Wei Wang
  6. Stephanie Blain-Moraes
  7. Nan Lin
  8. Kaitlyn Maier
  9. Maxwell Muench
  10. Vijay Tarnal
  11. Giancarlo Vanini
  12. E Andrew Ochroch
  13. Rosemary Hogg
  14. Marlon Schwartz
  15. Hannah Maybrier
  16. Randall Hardie
  17. Ellen Janke
  18. Goodarz Golmirzaie
  19. Paul Picton
  20. Andrew R McKinstry-Wu
  21. Michael S Avidan
  22. Max B Kelz
(2021)
Recovery of consciousness and cognition after general anesthesia in humans
eLife 10:e59525.
https://doi.org/10.7554/eLife.59525

Share this article

https://doi.org/10.7554/eLife.59525

Further reading

    1. Biochemistry and Chemical Biology
    2. Medicine
    Soo-Yeon Hwang, Kyung-Hwa Jeon ... Youngjoo Kwon
    Research Article

    HER2 overexpression significantly contributes to the aggressive nature and recurrent patterns observed in various solid tumors, notably gastric cancers. Trastuzumab, HER2-targeting monoclonal antibody drug, has shown considerable clinical success; however, readily emerging drug resistance emphasizes the pressing need for improved interventions in HER2-overexpressing cancers. To address this, we proposed targeting the protein-protein interaction (PPI) between ELF3 and MED23 as an alternative therapeutic approach to trastuzumab. In this study, we synthesized a total of 26 compounds consisting of 10 chalcones, 7 pyrazoline acetyl, and 9 pyrazoline propionyl derivatives, and evaluated their biological activity as potential ELF3-MED23 PPI inhibitors. Upon systematic analysis, candidate compound 10 was selected due to its potency in downregulating reporter gene activity of ERBB2 promoter confirmed by SEAP activity and its effect on HER2 protein and mRNA levels. Compound 10 effectively disrupted the binding interface between the ELF3 TAD domain and the 391–582 amino acid region of MED23, resulting in successful inhibition of the ELF3-MED23 PPI. This intervention led to a substantial reduction in HER2 levels and its downstream signals in the HER2-positive gastric cancer cell line. Subsequently, compound 10 induced significant apoptosis and anti-proliferative effects, demonstrating superior in vitro and in vivo anticancer activity overall. We found that the anticancer activity of compound 10 was not only restricted to trastuzumab-sensitive cases, but was also valid for trastuzumab-refractory clones. This suggests its potential as a viable therapeutic option for trastuzumab-resistant gastric cancers. In summary, compound 10 could be a novel alternative therapeutic strategy for HER2-overexpressing cancers, overcoming the limitations of trastuzumab.

    1. Medicine
    Jeong-Oh Shin, Jong-Bin Lee ... Jin-Woo Kim
    Research Article

    This study investigates the effects of two parathyroid hormone (PTH) analogs, rhPTH(1-34) and dimeric R25CPTH(1-34), on bone regeneration and osseointegration in a postmenopausal osteoporosis model using beagle dogs. Twelve osteoporotic female beagles were subjected to implant surgeries and assigned to one of three groups: control, rhPTH(1-34), or dimeric R25CPTH(1-34). Bone regeneration and osseointegration were evaluated after 10 weeks using micro-computed tomographic (micro-CT), histological analyses, and serum biochemical assays. Results showed that the rhPTH(1-34) group demonstrated superior improvements in bone mineral density, trabecular architecture, and osseointegration compared to controls, while the dimeric R25CPTH(1-34) group exhibited similar, though slightly less pronounced, anabolic effects. Histological and TRAP assays indicated both PTH analogs significantly enhanced bone regeneration, especially in artificially created bone defects. The findings suggest that both rhPTH(1-34) and dimeric R25CPTH(1-34) hold potential as therapeutic agents for promoting bone regeneration and improving osseointegration around implants in osteoporotic conditions, with implications for their use in bone-related pathologies and reconstructive surgeries.